Relapsing-remitting Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Relapsing-remitting Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-06-04Clinical Trial Update: Productive Value of Sonographic Measurement of Optic Nerve in Transitional Multiple
This clinical trial update evaluates whether sonographic measurement of the optic nerve is a productive diagnostic approach in Relapsing-Rem…
-
CLINICAL_TRIALS trial_result · 2024-05-17Clinical Trial Update: A Study for Tysabri Participant Preference
This clinical trial update covers a study evaluating participant preferences for Tysabri (natalizumab) in Relapsing-Remitting Multiple Scler…
-
CLINICAL_TRIALS trial_result · 2024-05-02Clinical Trial Update: A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis
This clinical trial update reports the completion of a study evaluating the effectiveness and safety of Mayzent (fingolimod) in Chinese pati…
-
CLINICAL_TRIALS trial_result · 2024-01-08Clinical Trial Update: Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients [Phase 4]
Phase 4 trial investigating effects of oral cladribine on remyelination and inflammation in relapsing-remitting multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2023-12-01Clinical Trial Update: A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS [Phase 3]
Phase 3 trial assessing efficacy, safety, and tolerability of monthly long-acting GA Depot IM injection in relapsing-remitting multiple scle…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-11-09Clinical Trial Update: Phase II Clinical Trial of OCH-NCNP1 [Phase 2]
Phase II clinical trial update for OCH-NCNP1 completed; study conditions include relapsing-remitting and secondary progressive multiple scle…
-
CLINICAL_TRIALS trial_result · 2023-07-03Clinical Trial Update: Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® [Phase 3]
Phase 3 trial evaluating the efficacy and safety of the biosimilar PB006 versus Tysabri in relapsing-remitting multiple sclerosis has comple…
-
CLINICAL_TRIALS trial_result · 2023-04-28Clinical Trial Update: Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS [Phase 3]
Non-inferiority Phase 3 trial comparing rituximab to ocrelizumab in relapsing multiple sclerosis is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2023-04-27Clinical Trial Update: Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis [Phase 4]
Phase 4 trial update on personalized extended interval dosing of natalizumab for relapsing-remitting multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2023-04-21Clinical Trial Update: A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis [Phase 2]
Phase 2 study update for orelabrutinib in relapsing-remitting multiple sclerosis is reported as ongoing with no published results yet.
-
CLINICAL_TRIALS trial_result · 2023-03-10Clinical Trial Update: Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis [Phase 1, Phase 2]
Clinical trial update for intranasal insulin in multiple sclerosis across Phase 1 and Phase 2 has been completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-12-21Clinical Trial Update: An Extension of the TG1101-RMS201 Trial [Phase 2]
An extension study of TG1101-RMS201 in relapsing-remitting multiple sclerosis has completed Phase 2.
-
CLINICAL_TRIALS trial_result · 2022-10-18Clinical Trial Update: Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis [Phase 3]
Phase 3 trial update on efficacy and safety of peginterferon beta-1a (CinnaGen) in relapsing remitting multiple sclerosis showed results aft…
-
CLINICAL_TRIALS trial_result · 2022-10-18Clinical Trial Update: Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis [Phase 3]
Phase 3 trial update for Xacrel (Ocrelizumab) in relapsing-remitting multiple sclerosis reports efficacy and safety data.
-
CLINICAL_TRIALS trial_result · 2022-09-28Clinical Trial Update: Vitamin D Supplementation in Multiple Sclerosis [Phase 3]
Phase 3 clinical trial evaluating vitamin D supplementation in relapsing-remitting multiple sclerosis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-09-16Clinical Trial Update: Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis [Phase 3]
Phase 3 clinical trial update assessing efficacy and safety of BCD-063 and Copaxone-Teva in relapsing-remitting multiple sclerosis has compl…
-
CLINICAL_TRIALS trial_result · 2021-09-05Clinical Trial Update: Tecfidera and the Gut Microbiota [Phase 4]
Phase 4 clinical trial update on Tecfidera (dimethyl fumarate) and its relationship with the gut microbiota in relapsing multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2021-08-05Clinical Trial Update: Study of Evobrutinib in Participants With RMS [Phase 3]
Phase 3 trial of evobrutinib in relapsing-remitting multiple sclerosis was terminated; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-08-05Clinical Trial Update: Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS) [Phase 3]
A Phase 3 clinical trial evaluating evobrutinib in relapsing-remitting multiple sclerosis was terminated, with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-07-29Clinical Trial Update: Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study) [Phase 1, Phase 2]
Clinical trial update for Sunphenon EGCG in relapsing-remitting multiple sclerosis (SuniMS) completed phases 1 and 2.
-
CLINICAL_TRIALS trial_result · 2021-07-28Clinical Trial Update: Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects [Phase 1]
Phase 1 comparative bioavailability study of BAFIERTAM (monomethyl fumarate) vs Tecfidera (dimethyl fumarate) in healthy subjects; completed…
-
CLINICAL_TRIALS trial_result · 2021-07-23Clinical Trial Update: Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 [Phase 4]
Phase IIIB-IV long-term follow-up study for CAMMS03409 in relapsing-remitting multiple sclerosis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-07-23Clinical Trial Update: MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS) [Phase 2]
A Phase 2 clinical trial update on IMU-838 (IMU-838) evaluating efficacy and safety in Relapsing-Remitting Multiple Sclerosis (RRMS) called …
-
CLINICAL_TRIALS trial_result · 2021-07-15Clinical Trial Update: Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis [Phase 2]
This Phase 2 trial update reports results for clemastine fumarate as a remyelinating agent in relapsing-remitting multiple sclerosis, with r…
-
CLINICAL_TRIALS trial_result · 2021-06-11Clinical Trial Update: Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis [Phase 2]
Phase 2 clinical trial evaluating ACT-128800 for efficacy, safety, and tolerability in relapsing-remitting multiple sclerosis; results were …